Detalhe da pesquisa
1.
Chronic graft-versus-host disease could ameliorate the impact of adverse somatic mutations in patients with myelodysplastic syndromes and hematopoietic stem cell transplantation.
Ann Hematol
; 98(9): 2151-2162, 2019 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-31312927
2.
Transcriptional and genomic characterization of measurable residual disease in acute myeloid leukaemia.
Br J Haematol
; 201(6): 1239-1244, 2023 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-37057357
3.
High-resolution copy number analysis of paired normal-tumor samples from diffuse large B cell lymphoma.
Ann Hematol
; 95(2): 253-62, 2016 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-26573278
4.
Simultaneous analysis of the expression of 14 genes with individual prognostic value in myelodysplastic syndrome patients at diagnosis: WT1 detection in peripheral blood adversely affects survival.
Ann Hematol
; 91(12): 1887-95, 2012 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-22875062
5.
Risk of placenta-mediated pregnancy complications or pregnancy-related VTE in VTE-asymptomatic families of probands with VTE and heterozygosity for factor V Leiden or G20210 prothrombin mutation.
Eur J Haematol
; 89(3): 250-5, 2012 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-22642978
6.
Interlaboratory Analytical Validation of a Next-Generation Sequencing Strategy for Clonotypic Assessment and Minimal Residual Disease Monitoring in Multiple Myeloma.
Arch Pathol Lab Med
; 146(7): 862-871, 2022 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34619755
7.
Prognostic value of FLT3 mutations in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline monochemotherapy.
Haematologica
; 96(10): 1470-7, 2011 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-21685470
8.
Prognostic significance of FLT3-ITD length in AML patients treated with intensive regimens.
Sci Rep
; 11(1): 20745, 2021 10 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-34671057
9.
Risk-adapted treatment of acute promyelocytic leukemia with all-trans retinoic acid and anthracycline monochemotherapy: long-term outcome of the LPA 99 multicenter study by the PETHEMA Group.
Blood
; 112(8): 3130-4, 2008 Oct 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-18664623
10.
Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma.
Blood Cancer J
; 10(10): 108, 2020 10 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-33127891